Vertex Pharmaceuticals Incorporated and Bio-Techne Corporation: SG&A Spending Patterns Compared

SG&A Spending Trends in Biotech Giants

In the dynamic world of biotechnology, understanding the financial strategies of industry leaders is crucial. Over the past decade, Vertex Pharmaceuticals and Bio-Techne Corporation have demonstrated distinct patterns in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Vertex Pharmaceuticals has consistently increased its SG&A spending, peaking at approximately $1.14 billion in 2023, marking a staggering 272% increase from 2014. This reflects Vertex's aggressive expansion and investment in operational capabilities.

Conversely, Bio-Techne Corporation has shown a more moderate growth in SG&A expenses, with a 554% increase from 2014 to 2024, reaching around $397 million. This steady rise indicates a strategic focus on sustainable growth and operational efficiency. Notably, data for Vertex in 2024 is missing, suggesting potential shifts in financial strategies or reporting. These trends highlight the contrasting approaches of these biotech titans in navigating the competitive landscape.